Biotech Values

[DewDiligence]

ABT, GSK ink deal for PLAME-antigen companion diagnostic:

http://finance.yahoo.com/news/Abbott-Expands-Agreement-GSK-prnews-2825674258.html?x=0

Under the expanded agreement, Abbott will develop a PCR test for use on the Abbott m2000rt™ instrument to screen non-small cell lung cancer tumors for the expression of the PRAME antigen. PRAME is a preferentially expressed antigen of melanoma that is expressed in 69% of non-small cell lung cancer cases, as well as in a wide variety of cancer types, including melanoma, breast, ovarian, and bladder cancer, with limited expression in normal cells.

Today’s announcement is an expansion of a cancer-biomarker collaboration the two companies inked in 2009 (#msg-39511634)